Relmada Therapeutics (RLMD) Non Operating Investment Income (2020 - 2026)
Relmada Therapeutics (RLMD) posted quarterly Non Operating Investment Income of -$9867.0 for Q1 2026, down 115.67% year-over-year from $62952.0 in Q1 2025, and down 102.67% quarter-over-quarter from $369538.0 in Q4 2025.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Non Operating Investment Income (2020 - 2026) Analysis & Trends
Relmada Therapeutics (RLMD) has reported Non Operating Investment Income for 7 consecutive years, with -$9867.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Investment Income fell 115.67% year-over-year to -$9867.0; the TTM figure through Mar 2026 stood at $264436.0 (up 336.64% YoY), while the FY2025 annual figure was $398255.0, up 5813.21% from the prior year.
- Non Operating Investment Income fell to -$9867.0 in Q1 2026 per RLMD's latest filing, from $369538.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $1.3 million in Q1 2023 and bottomed at -$3.3 million in Q4 2023.
- Historically, Non Operating Investment Income has averaged -$286858.1 across 5 years, with a median of -$33351.0 in 2022.
- Annual changes were most pronounced in 2023 — Non Operating Investment Income slumped 9932.59% — and 2024, when it soared 385.87%.
- Relmada Therapeutics' Non Operating Investment Income stood at -$33351.0 in 2022, then plunged by 9932.59% to -$3.3 million in 2023, then surged by 91.72% to -$277068.0 in 2024, then jumped by 233.37% to $369538.0 in 2025, then sank by 102.67% to -$9867.0 in 2026.
- Business Quant data shows RLMD's Non Operating Investment Income at -$9867.0 in Q1 2026, $369538.0 in Q4 2025, and -$81438.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Relmada Therapeutics | 498.39 Mn | 498.39 Mn | - | -167,258.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -167,258.00 |
| Mar 31, 2026 | -540,097.00 |
| Dec 31, 2025 | 186,045.00 |
| Sep 30, 2025 | -81,438.00 |
| Jun 30, 2025 | 47,203.00 |
| Mar 31, 2025 | 155,731.00 |
| Dec 31, 2024 | 40,844.00 |
| Sep 30, 2024 | 278,555.00 |
| Jun 30, 2024 | 133,114.00 |
| Mar 31, 2024 | 53,133.00 |
| Dec 31, 2023 | -3.35 Mn |
| Sep 30, 2023 | -579,147.00 |
| Jun 30, 2023 | -639,634.00 |
| Mar 31, 2023 | 1.29 Mn |
| Dec 31, 2022 | -323,120.00 |
| Sep 30, 2022 | -947,512.00 |
| Jun 30, 2022 | -1.19 Mn |
| Mar 31, 2022 | -1.76 Mn |
| Dec 31, 2021 | -122,684.00 |
| Sep 30, 2021 | -336,949.00 |